US2019256596A1PendingUtilityA1

Antibodies directed against lymphocyte activation gene 3 (lag-3)

62
Assignee: ANAPTYSBIO INCPriority: Feb 3, 2015Filed: May 1, 2019Published: Aug 22, 2019
Est. expiryFeb 3, 2035(~8.6 yrs left)· nominal 20-yr term from priority
Inventors:Helen Toni JunMarilyn KehryPeter BowersDavid J. King
C07K 2317/92C07K 2317/76A61K 39/3955C07K 2319/32C07K 2317/94A61P 31/00C07K 2319/30C07K 2317/524C07K 2317/71C07K 16/2803C07K 16/2818A61P 35/00A61K 2039/507C07K 2317/24A61K 2039/505C07K 2317/70Y02A50/386C07K 2317/30C07K 2317/56Y02A50/30C07K 2317/90
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.

Claims

exact text as granted — not AI-modified
1 - 42 . (canceled) 
     
     
         43 . A Lymphocyte Activation Gene-3 (LAG-3) binding agent comprising:
 an immunoglobulin light chain variable (V L ) region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:88; and   an immunoglobulin heavy chain variable (V H ) region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:182.   
     
     
         44 . The LAG-3 binding agent of  claim 43 , wherein the V L  region comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:88. 
     
     
         45 . The LAG-3 binding agent of  claim 43 , wherein the V L  region comprises an amino acid sequence that is identical to SEQ ID NO:88. 
     
     
         46 . The LAG-3 binding agent of  claim 43 , wherein the V H  region comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:182. 
     
     
         47 . The LAG-3 binding agent of  claim 43 , wherein the V H  region comprises an amino acid sequence that is identical to SEQ ID NO:182. 
     
     
         48 . The LAG-3 binding agent of  claim 43 , wherein the V L  region comprises an amino acid sequence that is identical to SEQ ID NO:88 and the V H  region is identical to SEQ ID NO:182. 
     
     
         49 . The LAG-3 binding agent of  claim 43 , wherein the LAG-3 binding agent is an antibody comprising an IgG4 constant region. 
     
     
         50 . A Lymphocyte Activation Gene-3 (LAG-3) binding agent comprising:
 an immunoglobulin light chain variable (V L ) region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3 of SEQ ID NO:88; and   an immunoglobulin heavy chain variable (V H ) region comprising a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of SEQ ID NO:182.   
     
     
         51 . The LAG-3 binding agent of  claim 50 , wherein the V L  region comprises SEQ ID NO:88 and the V H  region comprises SEQ ID NO:182. 
     
     
         52 . A method of treating a cancer or infectious disease comprising administering the Lymphocyte Activation Gene-3 (LAG-3) binding agent of  claim 50  to a subject in need of treatment. 
     
     
         53 . The method of  claim 52 , wherein the V L  region comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:88. 
     
     
         54 . The method of  claim 52 , wherein the V L  region comprises an amino acid sequence that is identical to SEQ ID NO:88. 
     
     
         55 . The method of  claim 52 , wherein the V H  region comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:182. 
     
     
         56 . The method of  claim 52 , wherein the V H  region comprises an amino acid sequence that is identical to SEQ ID NO:182. 
     
     
         57 . The method of  claim 52 , wherein the V L  region comprises an amino acid sequence that is identical to SEQ ID NO:88 and the V H  region comprises an amino acid sequence that is identical to SEQ ID NO:182. 
     
     
         58 . The method of  claim 52 , wherein the subject in need of treatment has cancer. 
     
     
         59 . The method of  claim 52 , wherein the cancer is selected from melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach cancer, salivary gland cancer, prostate cancer, pancreatic cancer, or Merkel cell carcinoma. 
     
     
         60 . The method of  claim 52 , further comprising administering a PD-1 binding agent. 
     
     
         61 . The method of  claim 52 , further comprising administering a TIM-3 binding agent. 
     
     
         62 . A pharmaceutical composition comprising an Lymphocyte Activation Gene-3 (LAG-3) binding agent and a pharmaceutically acceptable carrier, wherein the LAG-3 binding agent comprises:
 an immunoglobulin light chain variable (V L ) region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:88; and   an immunoglobulin heavy chain variable (V H ) region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:182.   
     
     
         63 . A method of treating a cancer or infectious disease comprising administering an Lymphocyte Activation Gene-3 (LAG-3) binding agent to a subject in need of treatment, wherein the LAG-3 binding agent comprises:
 an immunoglobulin light chain variable (V L ) region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:88; and   an immunoglobulin heavy chain variable (V H ) region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:182.   
     
     
         64 . The method of  claim 63 , wherein the V L  region comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:88. 
     
     
         65 . The method of  claim 63 , wherein the V L  region comprises an amino acid sequence that is identical to SEQ ID NO:88. 
     
     
         66 . The method of  claim 63 , wherein the V H  region comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:182. 
     
     
         67 . The method of  claim 63 , wherein the V H  region comprises an amino acid sequence that is identical to SEQ ID NO:182. 
     
     
         68 . The method of  claim 63 , wherein the V L  region comprises an amino acid sequence that is identical to SEQ ID NO:88 and the V H  region comprises an amino acid sequence that is identical to SEQ ID NO:182. 
     
     
         69 . The method of  claim 63 , wherein the subject in need of treatment has cancer. 
     
     
         70 . The method of  claim 63 , wherein the cancer is selected from melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach cancer, salivary gland cancer, prostate cancer, pancreatic cancer, or Merkel cell carcinoma. 
     
     
         71 . The method of  claim 63 , further comprises administering a PD-1 binding agent. 
     
     
         72 . The method of  claim 63 , further comprises administering a TIM-3 binding agent.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.